|Year : 2022 | Volume
| Issue : 2 | Page : 184-188
Tinnitus in COVID-19 patients: Our experiences at an eastern Indian tertiary care teaching hospital
Santosh Kumar Swain1, Somadatta Das2
1 Department of Otorhinolaryngology and Head and Neck Surgery, IMS and SUM Hospital, Siksha “O” Anusandhan University, Bhubaneswar, Odisha, India
2 Central Research Laboratory, IMS and SUM Hospital, Siksha “O” Anusandhan University, Bhubaneswar, Odisha, India
|Date of Submission||08-Jan-2022|
|Date of Decision||03-Dec-2022|
|Date of Acceptance||05-Dec-2022|
|Date of Web Publication||2-Jan-2023|
Dr. Santosh Kumar Swain
Department of Otorhinolaryngology and Head and Neck Surgery, IMS and SUM Hospital, Siksha “O” Anusandhan University, K8, Kalinga Nagar, Bhubaneswar - 751 003, Odisha
Source of Support: None, Conflict of Interest: None
Background: Tinnitus is a common otologic symptom found in the outpatient department of otolaryngology. Patients with COVID-19 infection have complained of tinnitus. However, in the present COVID-19 epidemic, it has received little attention. Objective: The goal of this study was to see how common tinnitus was among COVID-19 patients in a tertiary care teaching hospital. Materials and Methods: This is a prospective study that looked at 28 COVID-19 participants who had tinnitus. COVID-19 infection was confirmed in all of them using a nasopharyngeal swab reverse transcription–polymerase chain reaction (RT-PCR). The detailed history-taking clinical examination of the ear was done for the assessment of tinnitus and its outcome was analyzed. Results: There were 28 COVID-19 patients presented with tinnitus out of 212 patients infected with severe acute respiratory syndrome coronavirus-2. There were 16 (57.14%) men and 12 (42.85%) women out of 28 COVID-19 patients with tinnitus, with a male-to-female ratio of 1.33:1. Seven (25%) of the 28 patients had hearing loss, whereas 4 (14.28%) had balance issues. Out of 28 patients, 5 (17.85%) had symptoms of migraine. Conclusion: This study shows that COVID-19 patients may be affected by subjective otoneurological symptoms like tinnitus. Tinnitus is more common in male COVID-19 patients than in female. The associated symptoms of hearing impairment and balance issues should be anticipated along with tinnitus. More research is needed to figure out the specific pathophysiological process that causes this subjective ringing sensation in COVID-19 patients.
Keywords: Cochleovestibular symptoms, COVID-19, severe acute respiratory syndrome coronavirus-2, tinnitus
|How to cite this article:|
Swain SK, Das S. Tinnitus in COVID-19 patients: Our experiences at an eastern Indian tertiary care teaching hospital. Mustansiriya Med J 2022;21:184-8
|How to cite this URL:|
Swain SK, Das S. Tinnitus in COVID-19 patients: Our experiences at an eastern Indian tertiary care teaching hospital. Mustansiriya Med J [serial online] 2022 [cited 2023 Jun 4];21:184-8. Available from: https://www.mmjonweb.org/text.asp?2022/21/2/184/366627
| Introduction|| |
COVID-19 infection is a highly contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 patients' clinical manifestations include fever, body soreness, cough, loss of smell, and taste abnormalities, as well as moderate respiratory symptoms to acute respiratory distress syndrome. COVID-19 patients may also present with neurological manifestations along with respiratory problems. The neurological symptoms may be found in approximately 30% of COVID-19 patients. The neurotropic nature of SARS-CoV-2 is still being investigated. Neurologic manifestations such as headache, impaired consciousness, and dizziness have been reported in COVID-19 patients. Olfactory and taste disturbances are two neurological manifestations found in COVID-19 patients. In addition to the variety of clinical symptoms, some COVID-19 patients present neuro-otological manifestations such as dizziness, tinnitus, and otalgia. Although tinnitus is a common clinical symptom encountered in the outpatient department of otorhinolaryngology and often is due to otological etiology, also reported in a few cases of COVID-19 patients. Persistent tinnitus in patient results in a disturbing quality of life and often hinders the routine work of an individual. Although there is increasing evidence of neurological manifestations in COVID-19 infection, a neuro-otological symptom like tinnitus has been only partially investigated in the present pandemic. The aim of this study was to evaluate tinnitus among COVID-19 patients in a tertiary care teaching hospital.
| Materials and Methods|| |
This is a prospective study conducted at a tertiary care teaching hospital between November 2020 and December 2021. This study was approved by the Institutional Ethical Committee (IEC) with reference number IEC/IMS/SOAU//26/12.04.2020. The patients who recovered from proven COVID-19 infection and complaining of tinnitus were enrolled in this study. Patients having a positive nasopharyngeal swab for SARS-CoV-2, independent of illness severity or need for oxygen support during therapy, were included in this research. The recovery was defined as a negative report of RT-PCR. The patients who participated in this study were above the age of 18 years. COVID-19 patients with subjective hearing loss in at least one ear, hospitalization in an intensive care unit due to severe SARS-CoV-2 infection, history of acoustic trauma or prolonged noise exposure, presence of known audiological diseases before the diagnosis of COVID-19 infection or previous surgery, psychiatric disorder, cardiovascular diseases, or circulatory comorbidities were all excluded from the study. All the enrolled patients have signed their written informed consent for this study. All participants had a thorough medical examination, with pertinent information such as age, sex, duration, the severity of COVID-19 infection, and isolation/treatment location being recorded. All participants gave their informed consent to participate in this study and to the use of anonymized data from their survey replies [Table 1]. The risk factors such as diabetes mellitus, hypertension, and any steroid taken by the patient during the treatment period were documented. All participants were also asked about any loss of smell and taste sensation during or after treatment of COVID-19 infections. Otoscopic examinations and tuning fork tests for hearing assessment of the participants were done with the use of appropriate protective measures. Magnetic resonance imaging (MRI) was done in all cases with unilateral tinnitus to rule out any cerebellopontine angle lesions.
Statistical Packages for the Social Sciences (SPSS), version 20, SPSS Inc., Chicago, IL, USA, was used for the statistical analysis.
| Results|| |
In this study, 212 patients with positive nasopharyngeal/oropharyngeal swabs for SARS-CoV-2 were included in the study. Out of 212 patients, 28 (13.20%) presented with subjective tinnitus. The age range of the COVID-19 patients with tinnitus was 18–72 years with a mean age of 48.16 years (standard deviation [SD] ±12; median 49). Out of 28 COVID-19 patients with tinnitus, 16 (57.14%) males and 12 (42.85%) females with a male-to-female ratio of 1.33:1. Out of 28 COVID-19 patients with tinnitus, 9 (32.14%) had diabetes mellitus and 5 (17.85%) had hypertension. Out of 28 COVID-19 patients with tinnitus, 11 (39.28%) had taken steroids during the treatment period of COVID-19 infection [Table 2]. There were 13 (46.42%) patients who developed the decreased sensation of smell and 12 (42.85%) had decreased taste sensation out of 28 COVID-19 patients with tinnitus. There were 18 (64.28%) patients who described tinnitus as recurrent, whereas 10 (35.71%) patients presented with occasional or sporadic [Table 2]. There were 25 (89.28%) patients presented with tinnitus in both ears, whereas 3 (10.71%) of them presented with tinnitus in one ear. MRI scan of the brain was done in three patients those presented with unilateral tinnitus and showed normal findings. Out of 28 patients, 12 (42.85%) described tinnitus of fluctuating intensity in nature, 10 (35.71%) described persistently but with changing intensity in nature, 4 (14.28%) described continuous with the same intensity, and 2 (7.14%) described the pulsatile type of tinnitus [Table 2]. Out of 28 patients, 7 (25%) presented with hearing loss confirmed by pure-tone audiometry and 4 (14.28%) with a balance disorder. Out of 28 patients, 5 (17.85%) had symptoms of migraine. Out of 28 patients with COVID-19 infections, 6 (21.42%) had developed anxiety and depression during isolation at the time of treatment.
| Discussion|| |
Tinnitus has a major impact on the patient's quality of life. Viral infections often cause sensorineural hearing loss and tinnitus, majority of them typically involve/damage the hair cells of the inner ear; however, some of them can involve the auditory brainstem. COVID-19 infections are reported to be associated with otoneurological manifestations such as tinnitus and balance disorders. The neurotrophic and neuroinvasive nature are the typical features of SARS-CoV-2 [Figure 1]. One study showed brain involvement by coronavirus infection results in possible neuro-auditory impairment. The SARS-CoV-2 infection may directly involve the central nervous system or result in vascular injury causing vasculitis similar to the mechanism for varicella-zoster virus and human immunodeficiency virus (HIV). The vasculopathy of the SARS-CoV-2 infection can be a direct feature of hypercoagulability. COVID-19 infection causes damage to the cochlear outer hair cells, according to a study., Direct viral damage of the organ of corti, stria vascularis, or spiral ganglion, injury mediated by the patient's immune system against virally expressed proteins (cytomegalovirus), and immunocompromise resulting in secondary bacterial infection of the ear are some of the mechanisms behind damage to the peripheral auditory system, such as the cochlea (measles and HIV).
|Figure 1: Mechanism of SARS-CoV-2-induced tinnitus. SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2|
Click here to view
The involvement of the cochleovestibular system by SARS-CoV-2 and stress in the current COVID-19 pandemic results in cochlear symptoms like tinnitus. Because the COVID-19 pandemic is predicted to last longer, the health, social, and emotional consequences are likely to persist. COVID-19 individuals who are socially isolated, lonely, and have poor sleep are at the greatest risk of acquiring tinnitus. Patients with tinnitus frequently complain that health-care providers ignore them because they do not comprehend the problems that come with tinnitus and hearing loss. Tinnitus is substantially more troublesome for females and younger age groups under the age of 50 years during the COVID-19 pandemic. In this study, 57.14% of males and 42.85% of females with COVID-19 infections were suffered from tinnitus. The age range of the COVID-19 patients with tinnitus was 18–72 years with a mean age of 48.16 (SD ± 12; median 49) in this study.
Some COVID-19 patients present with olfactory dysfunction and taste dysfunction along with the presence of tinnitus due to the common mechanism of the neuroinvasive nature of SARS-CoV-2. In this study, 46.42% of COVID-19 patients with tinnitus presented with olfactory dysfunction, and 42.85% of COVID-19 patients with tinnitus presented with taste disorders. The factors which exacerbate tinnitus include self-isolation, experiencing loneliness, poor sleep, and reduced levels of physical exercise. Anxiety, depression, irritability, and financial worries during the pandemic period further contribute to more bothersome tinnitus. In this study, 21.42% of patients of COVID-19 patients with tinnitus had developed anxiety and depression during the isolation period. Although not always found, several patients manifested with tinnitus and deafness, with unilateral sensorineural hearing loss being the most commonly reported. The auditory symptoms in COVID-19 patients were documented to resolve in some patients and persisted for 6–7 months in COVID-19 patients by others. In this study, tinnitus of fluctuating intensity was found in 42.85% of COVID-19 patients with tinnitus, whereas persistent but changing intensity was found in 35.71% of cases.
The important diagnostic element of the patient with tinnitus is often medical history data.
As survivors of COVID-19 patients who were managed by ototoxic medicines such as chloroquine or hydroxychloroquine, a thorough history should be taken, as these treatments have been linked to an increased risk of deafness, tinnitus, and vertigo. Hearing difficulties, such as the onset or development of tinnitus, should be observed in COVID-19 patients. Detail audiological assessments are needed for patients with tinnitus which include tuning fork test, pure-tone audiometry, and tympanometry. Pure-tone audiometry testing and tympanometry by an audiologist in a soundproof room are helpful to rule out any hearing loss and tinnitus. In this study, 25% of COVID-19 patients with tinnitus presented with hearing loss. In the current pandemic, pure-tone audiometry and tympanometry should be performed with all safety measures for COVID-19. Tympanometry is done to assess the middle ear pathology and Eustachian tube function. Otoacoustic emissions (OAEs) are the kind of energy generated by cochlear outer hair cells. Spontaneous OAEs are usually recordable in the absence of deliberate external acoustic stimulation.[23a] TEOAEs are noninvasive and simple to carry out. This test needs lesser time, lesser cost, and higher sensitivity. TEOAE may exhibit a reduction in amplitude, indicating a modest degradation of the cochlea's outer hair cell functioning. COVID-19 infection has a negative impact on the outer hair cells of the cochlea, which affects the pure-tone audiogram low-frequency threshold as well as TEOAE and DPOAE low-frequency amplitudes. Decreased amplitude of TEOAEs and DPOAEs indicates damaged outer hair cells of the cochlea. To rule out any lesions in the brain and inner ear, MRI can be used. In this study, 10.71% of patients presented with tinnitus in one ear. MRI scan of the brain was done in these patients those presented with unilateral tinnitus and showed normal findings.
The most effective therapy for COVID-19 infections is still being researched urgently. It is always challenging for the clinician to identify the etiology of COVID-19 infections for cochleovestibular symptoms such as tinnitus and start appropriate treatment to get maximum clinical recovery. Evaluation for diabetes mellitus, hypertension, lipid profile, thyroid function tests, allergies, and variables that cause tinnitus, such as stress, coffee, aspirin, and nicotine use, must all be considered and controlled while treating tinnitus. In this study, 32.14% of patients with COVID-19 infections were associated with diabetes mellitus, and 17.85% of them were associated with hypertension. Pharmacological treatments such as lidocaine, antidepressants, benzodiazepines, and caroverine are tried and given some benefits for managing tinnitus. Gingko Biloba is also a common alternative medicine prescribed by several clinicians for the treatment of tinnitus. Tinnitus retraining therapy (TRT), masking, amplification, and minimizing triggering substances, as well as environmental variables, are among nonpharmacological therapeutic alternatives. Masking is a technique that uses an external sound to cover or partially conceal tinnitus. TRT is more successful than masking since it involves counseling and sound generator therapy.
| Conclusion|| |
There is growing evidence of otologic symptom disorders like tinnitus as part of clinical manifestations of COVID-19 infection. Tinnitus in COVID-19 infection has been described as neurotrophic and neuroinvasive capabilities of the SARS-CoV-2 virus. Recurrent tinnitus is more commonly found in this study. In many cases of COVID-19 patients with tinnitus, they were associated with comorbidities such as diabetes mellitus and hypertension. More research is needed to fully comprehend tinnitus in patients with SARS-CoV-2 infection and the persistence of this clinical entity long after infection, as well as a high-quality study with a large sample size to look at the impact of COVID-19 infections on the audiovestibular component.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.
Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci 2020;77:8-12.
Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al.
A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020;94:55-8.
Ralli M, Di Stadio A, Greco A, de Vincentiis M, Polimeni A. Defining the burden of olfactory dysfunction in COVID-19 patients. Eur Rev Med Pharmacol Sci 2020;24:3440-1.
Chan Y. Tinnitus: Etiology, classification, characteristics, and treatment. Discov Med 2009;8:133-6.
Meyer M, Luethi MS, Neff P, Langer N, Büchi S. Disentangling tinnitus distress and tinnitus presence by means of EEG power analysis. Neural Plast 2014;2014:468546.
Swain SK, Nayak S, Ravan JR, Sahu MC. Tinnitus and its current treatment – Still an enigma in medicine. J Formos Med Assoc 2016;115:139-44.
Munro KJ, Uus K, Almufarrij I, Chaudhuri N, Yioe V. Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. Int J Audiol 2020;59:889-90.
Swain SK, Pani SR. Incidence of hearing loss in COVID-19 patients: A COVID hospital-based study in the eastern part of India. Int J Curr Res Rev 2021;13:103-7.
Sriwijitalai W, Wiwanitkit V. Hearing loss and COVID-19: A note. Am J Otolaryngol 2020;41:102473.
Chetty R, Batitang S, Nair R. Large artery vasculopathy in HIV-positive patients: Another vasculitic enigma. Hum Pathol 2000;31:374-9.
Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al.
Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18:1738-42.
De Luca P, Scarpa A, De Bonis E, Cavaliere M, Viola P, Gioacchini FM, et al.
Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. Am J Otolaryngol 2021;42:102640.
Swain SK, Pani SR. Hearing loss: A neglected and morbid clinical entity in corona virus disease 2019 pandemic. Amrita J Med 2020;16:159-63. [Full text]
Abramovich S, Prasher DK. Electrocochleography and brain-stem potentials in Ramsay hunt syndrome. Arch Otolaryngol Head Neck Surg 1986;112:925-8.
Swain SK, Acharya S, Sahajan N. Otorhinolaryngological manifestations in COVID-19 infections: An early indicator for isolating the positive cases. J Sci Soc 2020;47:63-8. [Full text]
Beukes EW, Onozuka J, Brazell TP, Manchaiah V. Coping with tinnitus during the COVID-19 pandemic. Am J Audiol 2021;30:385-93.
Swain SK, Behera IC, Sahu MC. Tinnitus among children – Our experiences in a tertiary care teaching hospital of eastern India. Pediatr Pol 2017;92:513-7.
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al.
Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun 2020;89:594-600.
Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al.
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv 2020;12:24.
Prayuenyong P, Kasbekar AV, Baguley DM. Clinical implications of chloroquine and hydroxychloroquine ototoxicity for COVID-19 treatment: A mini-review. Front Public Health 2020;8:252.
Swain SK, Sahu MC, Choudhury J. Sudden sensorineural hearing loss in children: Our experiences in tertiary care teaching hospital of eastern India. Pediatr Pol Pol J Paediatr 2018;93:127-31.
a Marian V, Lam TQ, Hayakawa S, Dhar S. Spontaneous otoacoustic emissions reveal an efficient auditory efferent network. J Speech Lang Hear Res 2018;61:2827-32.
Swain SK, Das A, Sahu MC, Das R. Neonatal hearing screening: Our experiences at a tertiary care teaching hospital of eastern India. Pediatr Pol 2017;92:711-5.
Swain SK. Age related hearing loss and cognitive impairment-a current perspective. Int J Res Med Sci 2021;9:317-21.
Hallak B, Schneider A, Güntensperger D, Schapowal A. Standardized ginkgo biloba extract in the treatment of vertigo and/or tinnitus: A review of the literature. Adv Aging Res 2021;10:31-57.
[Table 1], [Table 2]